author-photo

S. Morales

Hospital Universitari Arnau de Vilanova

61

Papers

401

Citations

Citation Trend

Filter By

Papers (38) Sort By

Journal Conference Others

Abstract P2-13-01: Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer: Subgroup analyses from the phase III ExteNET trial

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens

2019 Clinical & Translational Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Abstract P5-20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Abstract P6-15-06: SOLTI-0702 CAPRICE: Final results of a phase II study of pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as neoadjuvant chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: 5-year overall survival disease free survival and late cardiac safety

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
NOLUS: a predictive model to identify Basal-like and HER2-enriched intrinsic subtypes based on estrogen receptor (ER), progesterone receptor (PR) and Ki67 immunohistochemistry (IHC) in hormone receptor-positive/HER2-negative (HR+/HER2–) breast cancer (BC)

2018 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
NorBreast-231 trial: a randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor positive, HER2-negative patients with advanced breast cancer

2018 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract OT2-01-06: Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. “The PEARL study” (GEICAM/2013-02)

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (9)
577PExosomal ECM1 protein expression in plasma from the tumor-draining vein (mesenteric vein) and time to relapse in colon cancer patients

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
200PVitamin D as a prognostic factor in triple negative early breast cancer

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
ACE and CXCL10 as predictive biomarkers in the LEA study

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)